Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
eBay (EBAY) PT Raised to $32 at Cantor Fitzgerald Following 1Q
-
UnitedHealth Group (UNH) PT Raised to $205 at Cantor Fitzgerald
-
NewLink Genetics (NLNK) PT Raised to $32 at Cantor Fitzgerald
-
Exponent (EXPO) PT Raised to $69 at Cantor Fitzgerald
-
Defense, finance, telecoms donated heavily to Trump inauguration: U.S. filing
-
Crohn's & Colitis Foundation Welcomes New National Trustees: Seven Join Leadership to Cure IBD and Improve Patient Quality of Life
-
Sorrento Announces Closing of Public Offering of Common Stock
-
Seabridge Gold Announces Closing of $15.7 Million Bought Deal Public Offering of Common Shares
-
Cantor Fitzgerald Downgrades PerkinElmer (PKI) to Neutral
-
Harmony Merger (HRMN) and NextDecade Announce $1.0B All-Stock Merger Agreement
-
NextDecade and Harmony Sign Definitive Merger Agreement, Agree to All-Stock Transaction Initially Valued at $1.0 Billion
-
UPDATE: Netflix (NFLX) PT Raised to $165 at Cantor Fitzgerald
-
ELS Reports First Quarter Results
-
Singulex Announces $50 Million Senior Secured Debt Facility with Perceptive Advisors
-
Sorrento Therapeutics (SRNE) Prices 23.63M Common Stock Offering at $2/Share
-
Sorrento Announces Pricing of Public Offering of Common Stock
-
Cantor Fitzgerald Reiterates Overweight Rating & $970 PT on Amazon (AMZN); 'Walmart Fires Another Salvo in Ecommerce Fight'
-
Cantor Fitzgerald Reiterates Overweight on Aerie Pharma (AERI) Following Announced Safety and Efficacy Results
-
Cantor Fitzgerald Remains Bullish on Netflix, Inc. (NFLX) Ahead of 1Q Report
-
Orchid Island Capital Announces April 2017 Monthly Dividend and March 31, 2017 RMBS Portfolio Characteristics
-
Sorrento Therapeutics (SRNE) Plans Offering of Common Stock
-
Sorrento Announces Proposed Public Offering of Common Stock
-
Cantor Fitzgerald Starts Prothena Corp (PRTA) at Overweight
-
PlacementTracker Publishes Q1 2017 Private Placement Market League Tables
-
Cantor Fitzgerald Reiterates Overweight on The Priceline Group (PCLN) Following 1Q Checks
-
Pre-Open Movers 04/11: (SALE) (TNXP) (MXWL) Higher; (CYTX) (AFSI) (SLP) Lower (more...)
-
INAP Signs Customized Colocation and Network Agreement in the Company's Flagship Dallas Data Center
-
TherapeuticsMD (TXMD): FDA Letter Implies PDUFA Date May Slide - Cantor
-
Cantor Fitzgerald Downgrades Wix.com (WIX) to Neutral on Valuation
-
After-Hours Stock Movers 09/01: (SALE) (MXWL) (AUPH) Higher; (CYTX) (SLP) (SEAC) Lower (more...)
-
Cantor Fitzgerald Starts Aurinia Pharmaceuticals (AUPH) at Overweight
-
Cantor Fitzgerald Reiterates Neutral Rating and $190 PT on Humana (HUM); 1Q Earnings Preview for 5/3 Report
-
AngioDynamics (ANGO) PT Raised to $21 at Cantor Fitzgerald Following Investor Day
-
Cantor Fitzgerald Reiterates Overweight Rating and $31 PT on Supernus Pharma (SUPN) Following Final FDA Approval of Trokendi XR for Migranes
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $197 at Cantor Fitzgerald; 'Xyrem Settlement Could Raise Ceiling for JAZZ Stock'
-
Cantor Fitzgerald Downgrades Teladoc (TDOC) to Neutral
-
Cantor Fitzgerald Reiterates Overweight and $24 PT on Corbus Pharmaceuticals (CRBP); 'Pivotal Systemic Sclerosis (SSc) Study Unveiled'
-
Cantor Fitzgerald Reiterates Overweight Rating and $25 PT on Corvus Pharmaceuticals (CRVS) Following CPI-444 Data Results
-
Cantor Fitzgerald Reiterates Overweight on UnitedHealth Group (UNH) Ahead of 1Q Report
-
Freddie Mac Prices $1.3 Billion Multifamily K-Deal, KF29
-
Paratek Pharmaceuticals (PRTK): Omadacycline Hits Primary Endpoints - Cantor
-
Cantor Fitzgerald Reiterates Overweight Rating and $34 PT on TherapeuticsMD (TXMD); 'Compelling TX-001 Data' Continues
-
Agile Therapeutics (AGRX) PT Raised to $9 at Cantor Fitzgerald Following KOL Call on Twirla
-
Rodin Global Property Trust Offering Declared Effective by the US Securities and Exchange Commission
-
NantHealth (NH) PT Lowered to $13 at Cantor Fitzgerald Following 4Q
-
Pre-Open Movers 03/31: (SORL) (BBRY) (BDSI) Higher; (DRIO) (BLRX) (CTSO) Lower (more...)
-
After-Hours Stock Movers 03/30: (AKTX) (VJET) (HIIQ) Higher; (DRIO) (BLRX) (CTSO) Lower (more...)
-
Orexigen Therapeutics (OREX) Enters $20M ATM Offering with Cantor Fitzgerald
-
Cantor Fitzgerald Starts Health Insurance Innovations (HIIQ) at Overweight; Sees a Double in the Stock
-
Cantor Fitzgerald Starts HealthEquity, Inc (HQY) at Overweight

